Evidence map›Paper›PMID 32468552›Full record

ArticleAdvances in experimental medicine and biology2020

ANTISOMA: A Computational Pipeline for the Reduction of the Aggregation Propensity of Monoclonal Antibodies.

Katerina C Nastou, Eleftheria G Karataraki, Nikos C Papandreou, Anna-Isavella G Rerra, Vassiliki P Grimanelli, Ilias Maglogiannis, Stavros J Hamodrakas, Vassiliki A Iconomidou

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katerina C NastouSection of Cell Biology and Biophysics, Department of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Eleftheria G KaratarakiSection of Cell Biology and Biophysics, Department of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Nikos C PapandreouSection of Cell Biology and Biophysics, Department of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Anna-Isavella G RerraSection of Cell Biology and Biophysics, Department of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Vassiliki P GrimanelliSection of Cell Biology and Biophysics, Department of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Ilias MaglogiannisDepartment of Digital Systems, University of Piraeus, Piraeus, Greece.
Stavros J HamodrakasSection of Cell Biology and Biophysics, Department of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Vassiliki A IconomidouSection of Cell Biology and Biophysics, Department of Biology, National and Kapodistrian University of Athens, Athens, Greece. veconom@biol.uoa.gr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) constitute a promising class of therapeutics, since ca. 25% of all biotech drugs in development are mAbs. Even though their therapeutic value is now well established, human- and murine-derived mAbs do have deficiencies, such as short in vivo lifespan and low stability. However, the most difficult obstacle to overcome, toward the exploitation of mAbs for disease treatment, is the prevention of the formation of protein aggregates. ANTISOMA is a pipeline for the reduction of the aggregation tendency of mAbs through the decrease in their intrinsic aggregation propensity, based on an automated amino acid substitution approach. The method takes into consideration the special features of mAbs and aims at proposing specific point mutations that could lead to the redesign of those promising therapeutics, without affecting their epitope-binding ability. The method is available online at http://bioinformatics.biol.uoa.gr/ANTISOMA .

Indexed as

Antibodies, MonoclonalComputational BiologyProtein Aggregation, PathologicalAnimalsEpitopesHumansMiceAntibodies, MonoclonalEpitopesIn silico modelsmAbsMonoclonal antibodiesProtein aggregation

Identifiers

PMID32468552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.